# Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

> **NCT00670397** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 11 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** HPPH

## Key facts

- **NCT ID:** NCT00670397
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-11
- **Final completion:** 2015-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** safety issues
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670397, "Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00670397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*